SAN DIEGO, Nov. 17 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN),
developer of advanced diagnostic products, announced today that its
subsidiary, Epoch Biosciences, was issued Patent No. 6,962,991, "Process for
the synthesis of pyrazolopyrimidines" by the U.S. Patent and Trademark Office.
The '991 patent relates to a process for the synthesis of pyrazolopyrimidine
nucleoside phosphoramidites. This process allows the economical production of
these important nucleic acid building components. The incorporation of
pyrazolopyrimidine bases into nucleic acid probes and primers in place of the
normal guanine (G) base allows the development of diagnostic assay reagents
that can target sequences intractable to normal probes and primers.
Efficient and accurate detection of nucleic acid targets play an integral
role in infectious and genetic disease management. Under normal
circumstances, nucleic acid sequences that have large stretches of G residues
have a tendency to bind together instead of binding to their complementary DNA
strand, making those sequences extremely difficult to design assays to detect.
Use of pyrazolopyrimidine-modified oligonucleotides can eliminate
self-association in primers and probes with high GC-content. This technology
allows Nanogen to develop highly sensitive amplification-based diagnostic
assays, solving a serious limitation in the traditional design of assays.
Often times these intractable sequences can code for genes altered by
mutations or changed by diseases such as cancer, so detection of molecular
events can be critical in managing patient treatment.
"Nanogen's technologies for molecular diagnostics uniquely position us to
develop assays for diseases that cannot be detected by other nucleic-acid
based technologies," noted Howard C. Birndorf, chairman and chief executive
officer of Nanogen. "This intellectual property distinguishes the real-time
PCR analyte specific reagents we're developing for these unmet needs in
diagnostics, which we'll use to secure a solid position in the rapidly growing
molecular testing market."
About Nanogen, Inc.
Nanogen's advanced technologies provide researchers, clinicians and
physicians worldwide with improved methods and tools to predict, diagnose, and
ultimately help treat disease. The company's products include real-time PCR
reagents, the NanoChip(R) electronic microarray platform and a line of rapid
diagnostic tests. Nanogen's ten years of pioneering research involving
nanotechnology holds the promise of miniaturization and continues to be
supported for its potential for diagnostic and biowarfare applications. For
additional information please visit Nanogen's website at www.nanogen.com.
This press release contains forward-looking statements that are subject to
risks and uncertainties that could cause actual results to differ materially
from those set forth in the forward-looking statements, including whether
patents owned or licensed by Nanogen will be developed into products, whether
the patents owned by Nanogen offer any protection against competitors with
competing technologies, whether products under development can be successfully
developed and commercialized, whether results reported by our customers or
partners can be identically replicated, and other risks and uncertainties
discussed under the caption "Factors That May Affect Results" and elsewhere in
Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and
Exchange Commission. These forward-looking statements speak only as of the
date hereof. Nanogen disclaims any intent or obligation to update these
SOURCE Nanogen, Inc.